PDACThe company advises on its website that they are planning an adaptive Phase3 program and intends to manage it directly within its Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024.
That is crystal clear. They are going it alone, and one has to assume with the info on the new presentation that Roche has agreed to continue supplying Tecentriq.
Maybe Anson will be supplying the funds. They never seem to have thought these matters out very carefully. At least they do not give their shareholders anything solid upon which to make decisions.